Navigation Links
ZEISS Ends Successful Fiscal Year 2012/13
Date:12/12/2013

STUTTGART, Germany, December 12, 2013 /PRNewswire/ --

Revenue Reaches New Record High

ZEISS has brought fiscal year 2012/13 to a successful conclusion (reporting date: 30 September 2013) with a new record high in revenue. The company generated revenue totaling EUR 4.190 billion (prior year: EUR 4.163 billion) and earnings (EBIT) of EUR 335 million (prior year: EUR 420 million). The Industrial Metrology and Medical Technology business groups recorded particularly strong growth. "In fiscal year 2012/13 we reached and partly exceeded our targets. ZEISS put in a good performance despite the challenging business environment and the weakness of the economy at the beginning of the year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss AG. "We made no compromises in our multi-year investment program - the biggest ever in the company's history - but continued to implement it consistently and systematically."

The number of employees increased to 24,623 worldwide. The company increased its expenditure on research and development activities by five percent to EUR 411 million. Investments in property, plant and equipment totaled EUR 245 million.

More information at http://www.zeiss.com/press

ZEISS is an international leader in the fields of optics and optoelectronics. The more than 24,000 employees of ZEISS generated revenue of about 4.2 billion euros in fiscal year 2012/13. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. ZEISS has been contributing to technological progress for more than 160 years. ZEISS develops and produces solutions for the semiconductor, automotive and mechanical engineering industries, biomedical research and medical technology, as well as eyeglass lenses, camera and cine lenses, binoculars and planetariums. ZEISS is present in over 40 countries around the glo
'/>"/>

SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ophthalmic Instrumentation - Global Strategic Business Report - 2012 Featuring Abbott, Bausch & Lomb, Carl Zeiss and Others
2. Carl Zeiss continúa en ruta hacia el crecimiento futuro e inversión
3. Carl Zeiss Continues on Track to Further Growth and Investment
4. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
5. Orexigen Announces Successful Interim Analysis of Contrave Light Study
6. QRxPharma Announces Successful Completion Of A$7.5 Million Placement
7. WuXi AppTec Successfully Completes Its First 2000L Disposable Bioreactor Run Using an NS0 Cell Line, Marking an Industry Milestone
8. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
9. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
10. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
11. Overcoming Regional Marketplace Complexities to Successfully Launch a Global Brand Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
(Date:12/24/2014)...  Conkwest, Inc., the Natural Killer Cell Company ... (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology ... NantWorks founder, physician scientist and biotechnology entrepreneur, has ... $48 million of the Company,s Class A Common ... be named Co-Chairman of the Conkwest Board of ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... 6 Roxane Laboratories, Inc. announced today the ... for Losartan Potassium Tablets USP, 25mg, 50mg and ... Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. Food ... immediate shipment to wholesalers and pharmacies nationwide. ...
... Texas, Oct. 6 DiFUSION Technologies Inc., a ... commercialization of its proprietary CleanFUZE™ anti-microbial technology for ... its new Xiphos™ line of posterior interbody devices ... spine, from L2 to SI, in skeletally mature ...
Cached Medicine Technology:Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion 2
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... during and after being treated with post-surgical chemotherapy did not ... from it, according to researchers at Dana-Farber Cancer Institute. ... characterized as cancer in the large bowel area with ... the researchers found that while multivitamin use had no beneficial ...
... of smoking cessation treatments are currently available for the ... smoking each year, but success rates vary widely. Despite ... smoking cessation treatment are needed to help smokers pick ... A major new personalized medicine clinical trial, led by ...
... an intense network of collaborative research. Building on a tool ... recent issue of Brain , Dr. Yaniv Assaf of ... international team of scientists to understand how different parts of ... into a "brain atlas." Brain researchers already know that ...
... disease deaths and hospital admissions, particularly among people from ... Journal of Epidemiology and Community Health . Current ... has improved the overall quality of primary care in ... evidence to suggest that better quality primary care actually ...
... on conserving the use of antibacterial drugs, or face ... antibiotic-resistant infections, according to an analysis out today. ... being depleted by resistance, which occurs when infection-causing microbes ... to widely-used treatments. Most proposals to solve this problem ...
... of California, San Diego School of Medicine have shown ... examining dynamic geometric patterns than they do looking at ... either typical or developmentally delayed toddlers. The results ... patterns early in life may be a signature behavior ...
Cached Medicine News:Health News:Multivitamin use doesn't impact colon cancer outcomes 2Health News:Penn receives $12 million NIH grant to research personalized approach to smoking cessation 2Health News:Mapping a brain atlas 2Health News:Primary care financial incentives cut heart disease deaths and admissions 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Visual pattern preference may be indicator of autism in toddlers 2Health News:Visual pattern preference may be indicator of autism in toddlers 3
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish....
Open wire style 16 mm blade with a wing tip twist giving the surgeon better on-axis accessibility....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Medicine Products: